Samsung Bioepis enters into commercialisation agreement for next-generation biosimilar candidates

This article was originally published here

SB11, a biosimilar candidate referencing LUCENTIS (ranibizumab), is undergoing phase 3 clinical trial, while SB15, a biosimilar candidate referencing EYLEAiii (aflibercept), is in pre-clinical development. In addition, the

The post Samsung Bioepis enters into commercialisation agreement for next-generation biosimilar candidates appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply